Literature DB >> 33327550

No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function.

Jun Wang1,2, Gang Greg Wang1,2.   

Abstract

Enhancer of zeste homolog 2 (EZH2) plays critical roles in a range of biological processes including organ development and homeostasis, epigenomic and transcriptomic regulation, gene repression and imprinting, and DNA damage repair. A widely known function of EZH2 is to serve as an enzymatic subunit of Polycomb repressive complex 2 (PRC2) and catalyze trimethylation of histone H3 lysine 27 (H3K27me3) for repressing target gene expression. However, an increasing body of evidence demonstrates that EZH2 has many "non-conventional" functions that go beyond H3K27 methylation as a Polycomb factor. First, EZH2 can methylate a number of nonhistone proteins, thereby regulating cellular processes in an H3K27me3-independent fashion. Furthermore, EZH2 relies on both methyltransferase-dependent and methyltransferase-independent mechanisms for modulating gene-expression programs and/or epigenomic patterns of cells. Importantly, independent of PRC2, EZH2 also forms physical interactions with a number of DNA-binding factors and transcriptional coactivators to context-dependently influence gene expression. The purpose of this review is to detail the complex, noncanonical roles of EZH2, which are generally less appreciated in gene and (epi)genome regulation. Because EZH2 deregulation is prevalent in human diseases such as cancer, there is increased dependency on its noncanonical function, which shall have important implications in developing more effective therapeutics.

Entities:  

Keywords:  EZH2; Polycomb repressive complex; cancer; chromatin; coactivator; gene transcription; histone; methylation

Year:  2020        PMID: 33327550     DOI: 10.3390/ijms21249501

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  11 in total

Review 1.  Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction.

Authors:  Yiran Guo; Shuai Zhao; Gang Greg Wang
Journal:  Trends Genet       Date:  2021-01-22       Impact factor: 11.639

2.  Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

Authors:  Leonie Ratz; Chiara Brambillasca; Hans Christian Reinhardt; Jos Jonkers; Julian Puppe; Leandra Bartke; Maxim A Huetzen; Jonas Goergens; Orsolya Leidecker; Ron D Jachimowicz; Marieke van de Ven; Natalie Proost; Bjørn Siteur; Renske de Korte-Grimmerink; Peter Bouwman; Emilia M Pulver; Roebi de Bruijn; Jörg Isensee; Tim Hucho; Gaurav Pandey; Maarten van Lohuizen; Peter Mallmann
Journal:  Breast Cancer Res       Date:  2022-06-17       Impact factor: 8.408

Review 3.  An overview of the development of EED inhibitors to disable the PRC2 function.

Authors:  Kai-Lu Liu; Kongkai Zhu; Hua Zhang
Journal:  RSC Med Chem       Date:  2021-10-21

4.  CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.

Authors:  Thomas Naert; Dieter Tulkens; Tom Van Nieuwenhuysen; Joanna Przybyl; Suzan Demuynck; Matt van de Rijn; Mushriq Al-Jazrawe; Benjamin A Alman; Paul J Coucke; Kim De Leeneer; Christian Vanhove; Savvas N Savvides; David Creytens; Kris Vleminckx
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 12.779

5.  Structure and Function of the Polycomb Repressive Complexes PRC1 and PRC2.

Authors:  Pierre-Olivier Angrand
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

6.  The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines.

Authors:  Andreas Schmidt; Lucas Behrendt; Jana Eybe; Steven W Warmann; Sabine Schleicher; Joerg Fuchs; Evi Schmid
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 7.  Long Non-Coding RNA Regulation of Epigenetics in Vascular Cells.

Authors:  Hester Garratt; Robert Ashburn; Miron Sopić; Antonella Nogara; Andrea Caporali; Tijana Mitić
Journal:  Noncoding RNA       Date:  2021-09-23

8.  Interplay between ceRNA and Epigenetic Control of microRNA: Modelling Approaches with Application to the Role of Estrogen in Ovarian Cancer.

Authors:  Tzy-Wei Huang; Frank H C Cheng; Ching-Cher Sanders Yan; Yu-Ming Chuang; Chien-Hong Cho; Hung-Cheng Lai; Shih-Feng Shieh; Michael W Y Chan; Je-Chiang Tsai
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

Review 9.  Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.

Authors:  Zhenyi Niu; Runsen Jin; Yan Zhang; Hecheng Li
Journal:  Signal Transduct Target Ther       Date:  2022-10-05

10.  lncRNA HCP5 acts as a ceRNA to regulate EZH2 by sponging miR‑138‑5p in cutaneous squamous cell carcinoma.

Authors:  Shibo Zou; Ya Gao; Shutang Zhang
Journal:  Int J Oncol       Date:  2021-07-01       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.